<p>The association between high-density lipoprotein cholesterol (HDL-C) levels and prognosis in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) remains unclear. This study aimed to investigate the relationship between HDL-C levels and all-cause mortality in this population. This multicenter prospective cohort study included 17,180 ACS patients who underwent PCI from the Multicenter Prospective Cohort Study on Acute Coronary Syndrome (MPCS-ACS). HDL-C levels were categorized into four groups: &lt; 30, 30–60, 60–90 (reference), and ≥ 90&#xa0;mg/dL. The primary endpoint was all-cause mortality. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), with multivariable adjustments. During a median follow-up of 49&#xa0;months, 1200 all-cause mortality events occurred. U-shaped associations were observed between HDL-C levels and risks of all-cause mortality. After multivariable adjustment, compared to patients with HDL-C levels of 60–90&#xa0;mg/dL, ACS patients with HDL-C &lt; 30&#xa0;mg/dL or ≥ 90&#xa0;mg/dL had a significantly increased risk of all-cause mortality, with HRs [95% CI] of 3.52 (2.66–4.64) and 2.71 (2.10–3.50), respectively. Both extremely low and high HDL-C levels were associated with increased risk of all-cause mortality in ACS patients undergoing PCI. Maintaining HDL-C levels within the 60–90&#xa0;mg/dL range may be associated with better long-term outcomes.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Association of HDL-C levels with all-cause mortality in ACS patients after PCI: a multicenter prospective cohort study

  • Hai-Tao Yang,
  • Jing-Kun Liu,
  • Zhi-hui Jiang,
  • Yi Yang,
  • Jing Zhang

摘要

The association between high-density lipoprotein cholesterol (HDL-C) levels and prognosis in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) remains unclear. This study aimed to investigate the relationship between HDL-C levels and all-cause mortality in this population. This multicenter prospective cohort study included 17,180 ACS patients who underwent PCI from the Multicenter Prospective Cohort Study on Acute Coronary Syndrome (MPCS-ACS). HDL-C levels were categorized into four groups: < 30, 30–60, 60–90 (reference), and ≥ 90 mg/dL. The primary endpoint was all-cause mortality. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), with multivariable adjustments. During a median follow-up of 49 months, 1200 all-cause mortality events occurred. U-shaped associations were observed between HDL-C levels and risks of all-cause mortality. After multivariable adjustment, compared to patients with HDL-C levels of 60–90 mg/dL, ACS patients with HDL-C < 30 mg/dL or ≥ 90 mg/dL had a significantly increased risk of all-cause mortality, with HRs [95% CI] of 3.52 (2.66–4.64) and 2.71 (2.10–3.50), respectively. Both extremely low and high HDL-C levels were associated with increased risk of all-cause mortality in ACS patients undergoing PCI. Maintaining HDL-C levels within the 60–90 mg/dL range may be associated with better long-term outcomes.